Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCBC
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The MCBC regimen is a modified dual alkylator-conditioning regimen employed in the pretreatment of refractory or relapsed Acute Myeloid Leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This regimen combines the chemotherapeutic agents Melphalan, Cladribine, Busulfan, and Cyclophosphamide. Its primary objective is to effectively eradicate leukemia blasts and mitigate the risk of early relapse, demonstrating significant anti-leukemia activity with manageable toxicity.
02
Targets
DNA
Beyond the preview
Go deeper on MCBC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCBC.